Drug Metabolism and Pharmacokinetics

Article	Citations
Refined CYP2E1∗ Template∗∗ system to decipher the ligand-interactions	179
Functional assessment of immortalized human brain microvascular endothelial cells with different passage numbers: A case study for a prospective proposal on variability management of in vitro blood-br	90
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity	55
Protection of mice against carbon tetrachloride-induced acute liver injury by endogenous and exogenous estrogens	47
CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children	23
Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model	21
Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum	21
Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms	21
Functional characterization of human organic anion transporter 10 (OAT10/SLC22A13) as an orotate transporter	15
The refined CYP2B6-Template system for studies of its ligand metabolisms	14
Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development	13
Drug induced organ toxicity: Transporter roles and derisking approaches	12
Potential ADME-related issues for PROTACs	12
Identification and characterization of novel metabolites of F2-isoprostanes	12
Assessing victim drug-drug interaction – Reaction phenotyping of CYP and non-CYP	12
Unveiling the intracellular journey: GOLGA8N-mediated subcellular trafficking of siRNA drugs and its implications on silencing efficacy	11
Modern pediatric drug development: Practical case examples and regulatory outcomes from novel applications of modelling	11
Successful optimization of pharmacokinetics and pharmacodynamics of oral cyclic peptide PCSK9 inhibitors	11
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant	10
Establishment of the relay method for low-turnover compounds in hepatocyte	9
Prediction and validation of human hepatobiliary clearances and hepatic concentrations of transported drugs using the relative expression factor (REF) and PET imaging approaches	9
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction by tucatinib	9
The spectrum of hepatic clearance models, from old to new	9
Synthesis and characterization of human metabolites of the echinocandid drug rezafungin by microbial biotransformation	9
UGT-mediated clearance IVIVE may be improved using relative activity factor approach	8

A practical approach for measuring acyl glucuronide migration half life	8
Monocarboxylate transporter 10: substrate-dependent mode of transport	8
The effect of traditional herbal medicine on the permeability of clarithromycin and loxoprofen in CACO-2 cell model	8
Stereoisomer separation of drugs and biomarkers using supercritical fluid chromatography to support PK/PD studies	7
Metabolism of DHED in vitro and in vivo to support drug optimization	7
Can LS180 cells predict metabolism and drug-drug interaction potential of UGT2B17 substrates?	7
Verification of a physiologically based pharmacokinetic model of caffeine that incorporates mechanistic descriptors of absorption	7
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human	7
Dynamic free fraction: concept, methodology and impact on hepatic clearance prediction using the well-stirred model	7
Utilizing various plasma protein binding tools for free fraction determination of lipophilic and lipopeptide drugs	7
Evaluation of a cost-effective in vitro human model for predicting intrinsic hepatocyte clearance of slowly metabolized compounds	6
Assessment of covalent binding body burden in Hmrel human hepatocyte co-culture model for metabollically low turnover compounds	6
Enriching metabolite fractions for assessment of AHR activation potential: a proof of concept study	6
Exploration of bioactivation of a branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor	6
Plasma protein binding of oligonucleotides using rapid agarose gel electrophoretic mobility shift assay	6
Redox metabolism in intestine and liver aggravates retronecine-type pyrrolizidine alkaloids-induced liver injury	6
Validation of LC-MS/MS method for the quantification of buprenorphine and its metabolites in rat’s blood, oral fluid, salivary gland and application the assay on pharmacokinetic study	6
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics	6
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics	5
Synthetic mRNA for ex vivo therapeutic applications	5
Adenosine deaminases acting on RNA modulate the expression of the human pregnane X receptor	5
Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality	5
Feature importance of machine learning prediction models shows structurally active part and important physicochemical features in drug design	5
Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam	5
Jasmone, an essential oil component, is an antagonist of aryl hydrocarbon receptor in liver and intestinal cells	5
Understanding the role of CYP3A in the metabolism of kinase inhibitors marketed in the past decade to better manage the risk of clinical drug-drug interactions	5
Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders	5
Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human	5
Formation of reactive metabolites of benzbromarone in humanized-liver mice	5
Novel food drug interaction mechanism involving acyclovir, chitosan and endogenous mucus	5
Clinical studies on pharmacogenomics and DDIS involving drug transporters	5
Latest developments in nitrosamine structure-activity relationships for carcinogenicity	5
Physiologically based pharmacokinetic model analysis of the inhibitory effect of vonoprazan on the metabolic activation of proguanil	5
Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes	5
Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis	5
A novel method for predicting the unbound valproic acid concentration	5
Human aldo-keto reductase (AKR) 1C1 and 1C2 act as coactivators of pregnane X receptor, a master regulator of drug-metabolizing and gluconeogenesis enzymes	4
Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model	4
Basic tenets for the ADME of protein therapeutics	4
Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolab	4
In vitro metabolism of the new antifungal dapaconazole using liver microsomes	4
Corrigendum to “Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration” [Drug Metabol Pharmacokinet 41 (2021) 100408]	4
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors	4
Functional characteristics of equilibrative nucleoside transporter 2 (ENT2/SLC29A2) for the transport of urate as a newly identified substrate	4
Effect of linker-payload design on the PK of ADCS	4
Applications of model simulation in pharmacological fields and the problems of theoretical reliability	4
Buffer compositions strongly impact the in vitro assessment of CYP fraction metabolized using human liver microsomes or expressed isoenzymes	4
Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs-	4
Story of maturation - Modelers vs models in the paediatric space	4
Enzyme induction fundamentals, assays, data interpretation and in vivo translation	4

Relative expression versus activity factor (ref vs. raf) to estimate fractional contribution of individual UGT isoforms (FGLUC) in drug glucuronidation	4
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation	4
Hepatocyte formation, reactivity, and stability differences of acyl glucuronide and acyl coenzyme a conjugates	3
This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta	3
Opportunities and challenges in drug development for retinal diseases	3
Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib	3
The practical impact of the FDA draft guidance on human mass balance studies – a year of client discussions	3
From stratified dose adjustment to personalised dosing: Linking LCMS proteomics in tissues to more clinically practical liquid biopsy samples – Opportunities and challenges	3
Cannabinoid-induced drug-drug interactions with hydromorphone.	3
The characterization of the pharmacokinetic profile of anti-tumor B (ATB) in oral cancer patients	3
Evaluation of a novel, primary human hepatocyte tri-culture model, truvivotm, for its ability to predict metabolic clearance of CYP, UGT, and AO substrates	3
In vitro and in vivo interactions between nicotine and the cannabis terpene limonene	3
Pharmacokinetic interaction of caffeine and theophylline in mice	3
Mathematical modeling of affinity design goals for CIS-binding BI-specific antibody-based molecules	3
One size does not fit all: Preclinical tools to characterize the pharmacokinetics and biodistribution of GaINAc-siRNA	3
Evaluation of biliary excretion process of drugs and bile acids using permeation assay by a novel in vitro hepatocyte culture system (ICHEP)	3
Lysosomal trapping measurement in multiple cell types using a high content imaging (HCI) system	2
What is the role of CYP1A1 in drug metabolism?	2
Human liver chimeric mouse and trasngenic animals are useful tools for quantitatively predicting clearance and drug-drug interactions in human	2
Exploring the human 3D small intestinal model (epiintestinaltm) for improved prediction of oral absorption, metabolism and complex drug-drug interactions of small molecule drugs	2
Novel approaches and troubleshooting for developing a high-throughput oligonucleotide LC-MS method beyond the current stage	2
Plasma protein binding in special populations: do current PBPK models correctly account for potential changes to fraction unbound?	2
Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS	2
Prediction of human clearance using human liver microsomes and hepatocytes with 455 drugs	2
Strategies for enhancing oral exposure of water-insoluble compounds	2
Deciphering the cell and zonal distribution of drug metabolizing enzymes and transporters in humans by single cell transcriptomics	2
Novel multi-tissue chips for predictive pharmacokinetic studies	2
Physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product	2
Pharmacokinetics of ginsenosides and effect of the lactic acid bacteria on pharmacokinetics of ginsenosides in mice and human	2
DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges	2
Quantitation and characterization of glucosylsphingosine in cerebrospinal fluid (CSF), plasma, and brain of monkey model with Gaucher disease	2
Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance	2
Optimization of methods for reducing turnaround time and compound consumptionwith echo liquid handling and automation enabling high capacity analysis for ADME screening	2
In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition	2
Using quantitative systems pharmacology (QSP) models to characterize the PK of novel drug modalities	2
Comparison of clearance and metabolic pathways in suspension hepatocytes and hepatopac cultures	2
An approach using a gamma-distributed delay model to evaluate the anticancer effect of doxorubicin-encapsulated polymeric micelles by predictive pharmacokinetic-pharmacodynamic modeling	2
An overview of CDE technical guideline for nonclinical study of ADCS: importance and strategy of studying release of payload-containing components from ADC and their further metabolism	2
Title page	2
Gene and Oligonucleotide Delivery	2
Development of a fluorescent-labeled trapping reagent to evaluate the risk posed by acyl-CoA conjugates	2
In vivo and in vitro biotransformation of molnupiravir (MOV), An oral prodrug of the antiviral ribonucleoside analog Β-D-N4-hydroxycytidine (NHC)	2
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants	1
Characteristics of membrane transport, metabolism, and target protein binding of cyclic depsipeptide destruxin E in HeLa cells	1
Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activity	1
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources	1
Identification of miRNAs that regulate human CYP2B6 expression	1
Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice	1
Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice	1
Application of machine learning techniques in population pharmacokinetics/pharmacodynamics modeling	1
Advanced in vitro evaluation of drug-induced kidney injury using microphysiological systems in drug discovery and development	1
In vitro uptake of an MC3 lipid nanoparticle formulation by mice, non-human primate, and human hepatocytes and Kupffer cells	1
A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study	1
Gene and oligonucleotide delivery via micro- and nanobubbles by ultrasound exposure	1
Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations	1
Functional role of serine 318 of the proton-coupled folate transporter in methotrexate transport	1
Systematic identification and characterization of cynomolgus macaque solute carrier transporters	1
Effect of antibiotic-administration period on hepatic bile acid profile and expression of pharmacokinetic-related proteins in mouse liver, kidney, and brain capillaries	1
Adenovirus vector-based vaccine for infectious diseases	1
Human brain organoids for understanding substance use disorders	1
Pharmacogenomics research and its clinical implementation in Thailand: Lessons learned from the resource-limited settings	1
Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers	1
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template	1
Appreciation to Reviewers	1
Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics	1
Constitutive androstane receptor-responsive elements for mouse Cyp1a2 transcriptional activation induced by constitutive androstane receptor ligands	1
Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation	1
Assessing complex drug-drug interactions using the truvivotm hepatocyte model	0
Novel coc-based liver tissue chip for predictive pharmacokinetic and toxicology applications	0
Impact of donor diversity on phase I and phase II activities in cryopreserved human hepatocytes and human liver microsomes	0
Assessment of the clinical pharmacokinetic interaction potential mediated So-Cheong-Ryong-Tang on a cocktail of anti-inflammatory and anti-biotic drugs, established by physiologically based pharmacoki	0
Identification and characterization of erlotinib as a potent mechanism-based inactivator of human aldehyde oxidase	0
Liver targeted therapy: What mist and DDI data mean for efficacy	0
Metabolism and excretion of therapeutic peptides: current industry practices and recommendations	0
Determination of metabolic pathways of phosphatidylcholine and lysophosphatidylcholine using a stable isotope tracer in hepatocarcinoma cell lines	0
Clinical DDI trial design and impact on product labels	0
Construction of a fused grid-based CYP2C18-Template system and its application to drug metabolism	0
Effect of deuteration on the single dose pharmacokinetic properties and postoperative analgesic activity of methadone	0
Development of a novel in silico classification model to assess reactive metabolite formation in cysteine trapping assay and investigation of important substructures	0
Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study	0

Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources	0
Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity	0
An overview of selected topics in the clinical pharmacology and translation of in vivo CRISPR-based therapies	0
Opportunities for microphysiological systems from the view of Japanese industries	0
Comparison of human biopsy-derived and human iPS cell-derived intestinal organoids established from a single individual	0
Hepatocyte CEBPA restricts the progression of liver fibrosis	0
In silico approach shows good predictability for free fraction in plasma and volume of distribution in human for drugs subjected to lysosomal trapping	0
Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery	0
Predicting drug metabolism and pharmacokinetics features of in-house compounds by a hybrid machine-learning model	0
Systematic investigation of the metabolism of cannabinoids by human cytochrome p450s	0
Translational PK/PD of the targeted radioligand therapy pluvicto	0
Update on next generation sequencing of pharmacokinetics-related genes: Development of the PKseq panel, a platform for amplicon sequencing of drug-metabolizing enzyme and drug transporter genes	0
Comparative analysis of microcystin toxicity in 2D and 3D cultured primary human hepatocytes	0
Construction of a fused grid-based CYP2C19-Template system and the application	0
Apple-derived extracellular vesicles modulate the expression of human intestinal bile acid transporter ASBT/SLC10A2 via downregulation of transcription factor RARα	0
Identification and characterisation of a novel amino acid conjugate; ergothioneine conjugate of raloxifene through in vitro and in vivo studies	0
Phenolsulfonphthalein as a surrogate substrate to assess altered function of the prostaglandin transporter SLCO2A1	0
Effect of substrate concentration on reactive metabolite assessment in drug discovery research	0
Risk of pharmacokinetic drug-drug interactions with novel drugs approved by the US FDA in 2022: a detailed review of DDI data from NDA documentation	0
In vitro evaluation of PROTAC® degrader ARV-766 for cytochrome P450- and transporter-mediated drug-drug interaction	0
Improvement of transdermal absorption rate by nonthermal biocompatible atmospheric pressure plasma	0
Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions	0
Protein-bound uremic toxin clearance as biomarkers of kidney tubular function in diabetic kidney disease	0
Method development to correct tissue concentrations for residual blood: Application to drug distribution in brain tumors	0
Projections for future challenges and opportunities for pharmacokineticists	0
Increasing the therapeutic index of ADCs with payload binding selectivity enhancers	0
Investigation of the learning process of diverse compound structures by chemical language models toward toxicity prediction	0
Inhibition of cytochrome P450 3A4 enzyme activity by alkaloid psilocin from magic mushrooms: potential for drug interactions	0
Designing novel RNA medicines for the brain	0
A synthetic G protein-coupled receptor 40 agonist GW9508 mitigates airway inflammation and mucus secretion in allergic asthma	0
Is CYP3A4 induction a good indicator for CYP2CS in cryopreserved human hepatocytes?	0
Omics analyses and their application for the discovery of biomarkers reflecting drug efficacy and adverse reaction	0
An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals	0
Clotrimazole is a potent and selective UGT2B4 chemical inhibitor	0
Preferential meropenem absorption activated by 1α,25-dihydroxyvitamin D3 and shared with foscarnet, a phosphate transporter substrate, in the rat ileum	0
Preface: In silico technologies to facilitate drug development	0
Toxicity of trimethoprim and sulfamethoxazole	0
Establishment of endogenous canine MUC1 knock-out MDCKII cells using CRISPR-Cas9 and evaluation of drug permeation	0
Exosomes: Breast cancer-derived extracellular vesicles; recent key findings and technologies in disease progression, diagnostics, and cancer targeting	0
Intestinal microbiota-mediated biotransformations alter the pharmacokinetics of the major metabolites of azathioprine in rats after oral administration	0
Inhibiting uptake activity of organic anion transporter 2 by bile acids	0
Metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) by Streptomyces griseolus CYP105A1 and its variants	0
Food effects on oral drug absorption: Recent advances in understanding mechanisms and quantitative prediction	0
In vitro evaluation of metabolism- and transporter-based drug interactions with sunscreen active ingredients	0
Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics	0
Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury	0
Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology	0
Recent studies on metabolism, DNA adducts, and biomarkers of tobacco carcinogens	0
Population pharmacokinetic and exposure-response analysis to support a dosing regimen of CPX-351 (NS-87) in Japanese adult and pediatric patients with untreated high-risk acute myeloid leukemia	0
In vitro metabolic stability and in vivo phaarmacokinetic behavior of panobinostat in mouse models for the treatment of CNS tumors	0
An in vitro microphysiological model of subcutaneous delivery	0
Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics	0
Strategies for DDI risk assessment between novel oncology agents and combination generic standard of care (SOC) agents	0
Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice	0
High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in t	0
Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration	0
Use of human liver microsomes to assess flavin-containing monooxygenase (FMO) metabolism in vitro	0
Evaluation and prediction of oral drug absorption and bioequivalence with food-druginteraction	0
Practical use of mechanistic modeling to discern real word complex drug interactions	0
Challenges associated with the biomarker-informed PBPK modeling of renal transporter-mediated drug interactions	0
Development of a high throughput screen for cytochrome P450-ligand binding assays	0
Evaluation of CYP450 activity in HLM bound to magnetizable beads	0
Experimental validation of the reliability of dilution method for plasma protein binding assay in human plasma using 12 commercial compounds	0
Investigating protein-mediated uptake drug-drug interactions using F-methotrexate as a substrate for OATP1B1 transporter	0
WITHDRAWN: Drugs that induce and inhibit cytochrome P450. A study with real-world evidence	0
Metabolic pathways of aschantin in human liver preparations	0
The mass balance, recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: metabolite characterisation	0
Inhibitory effects of indoxyl sulfate and creatinine on the renal transport of meropenem and biapenem in rats	0
Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants	0
LC-MS for identifying changes (or lack of it) in ADME across different cohorts	0
Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder	0
Physiological effects of food ingredients on intestinal epithelial cell function	0
In vitro liver models for toxicological research	0
Delivery of small interfering RNAs by nanovesicles for cancer therapy	0
Investigating catechin-mediated effects on drug solubility as a mechanism underlying a green tea-raloxifene pharmcokinetic interaction	0
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria	0
Phosphate buffer interferes dissolution of prazosin hydrochloride in compendial dissolution testing	0
Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats	0
Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions	0
Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase	0
Air–liquid interface culture and modified culture medium promote the differentiation of human induced pluripotent stem cells into intestinal epithelial cells	0
Therapeutic application of sequence-specific binding molecules for novel genome editing tools	0
CYP46A1 inhibition and activation: an in vitro high throughput screening assay to assess possible drug interactions using FDA approved chemical library	0
Novel approach to determine plasma protein binding for labile compounds using equilibrium dialysis	0
Drug metabolism by the human gut microbiome	0
Establishment of MDR1-knockout human enteroids for pharmaceutical application	0
Development of a HRMS-MS method for measuring plasma 4Β-hydroxycholesterol, an endogenous biomarker of CYP3A activity, in monkeys treated with CYP3A modulators	0
The distribution of perfluorooctanesulfonate (PFOS) into the liver is not dependent on fatty acid binding protein (FABP)	0
Pharmacokinetics of genistein distribution in blood and retinas of diabetic and non-diabetic rats	0
Interactions of sutezolid and its active metabolite with human transporters	0
Publisher's note	0
Oligonucleotide delivery to antigen presenting cells by using schizophyllan	0
Tenofovir activation is diminished in the brain and liver of creatine kinase brain-type knockout mice	0
Development of quantitative translational model of neutropenia using nonclinical animal data and physiological parameters	0
Roles of human cytochrome P450 3A4/5 in dexamethasone 6β-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin	0